Cited by 403Systemic Lupus Erythematosus ResearchRenal Diseases and GlomerulopathiesSystemic Sclerosis and Related Diseases

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways

Open access
the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Der, Evan, Suryawanshi, Hemant, Morozov, Pavel, Kustagi, Manjunath, Goilav, Beatrice, Ranabothu, Saritha, Izmirly, Peter +19 more·2019·Nature Immunology

Abstract

The molecular and cellular processes that lead to renal damage and to the heterogeneity of lupus nephritis (LN) are not well understood. We applied single-cell RNA sequencing (scRNA-seq) to renal biopsies from patients with LN and evaluated skin biopsies as a potential source of diagnostic and prognostic markers of renal disease. Type I interferon (IFN)-response signatures in tubular cells and keratinocytes distinguished patients with LN from healthy control subjects. Moreover, a high IFN-response signature and fibrotic signature in tubular cells were each associated with failure to respond to treatment. Analysis of tubular cells from patients with proliferative, membranous and mixed LN indicated pathways relevant to inflammation and fibrosis, which offer insight into their histologic differences. In summary, we applied scRNA-seq to LN to deconstruct its heterogeneity and identify novel targets for personalized approaches to therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41590-019-0386-1

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two studies demonstrated mesenchymal progenitor hierarchy, diversity in the pathophysiological roles of their progeny, and context-dependent fate determination.

    “two studies, focussing on populations of hypermethylated in cancer protein (Hic1)+Pdgfrα+ lymphocyte antigen 6 complex (LY6A)+ MP populations in heart and skeletal muscle, have elegantly demonstrated MP hierarchy, diversity in the pathophysiological roles of their progeny, and how fate determination of MP is context dependent31,32.”

    From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [31]

  • Although Hic1 inactivation in skeletal muscle results in marked expansion of Pdgfrα+LY6A+ cells during homeostasis, it does not increase skeletal muscle fibrosis and has no substantial effect on skeletal muscle regeneration.

    “although Hic1 inactivation in skeletal muscle also resulted in a marked expansion of Pdgfrα+LY6A+ cells during homeostasis, this did not increase skeletal muscle fibrosis and had no substantial effect on skeletal muscle regeneration31”

    From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [31]

  • Conditional genetic inactivation of Hic1 in mice leads to activation and expansion of mesenchymal progenitors in both heart and skeletal muscle, demonstrating that Hic1 is required for maintaining mesenchymal progenitor quiescence.

    “Conditional genetic inactivation of Hic1 in mice led to activation and expansion of MPs in both heart and skeletal muscle, demonstrating that Hic1 is required for maintaining MP quiescence.”

    From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [31]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Der, E., Suryawanshi, H., Morozov, P., Kustagi, M., Goilav, B., Ranabothu, S., Izmirly, P., Clancy, R., Belmont, H. M., Koenigsberg, M., Mokrzycki, M., Rominieki, H., Graham, J. A., Rocca, J. P., Bornkamp, N., Jordan, N., Schulte, E., Wu, M., Pullman, J., Slowikowski, K., Raychaudhuri, S., Guthridge, J., James, J., Buyon, J., Tuschl, T., & Putterman, C.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Rockefeller University (US)
  • Arkansas Children's Hospital (US)
  • New York University (US)
  • Montefiore Medical Center (US)
  • Broad Institute (US)
  • Oklahoma Medical Research Foundation (US)
Corresponding author
  • Buyon, Jill
  • Tuschl, Thomas
  • Putterman, Chaim
Venue
Nature Immunology
Published
2019-05-20
Volume
20
Issue
7
Pages
915-927
ISSN
  • 1529-2908 (ISSN-L)
  • 1529-2916
OpenAlex
W2944872709
Cited by
403
References
52
Citations by year
2026: 30 · 2025: 35 · 2024: 61 · 2023: 44 · 2022: 86 · 2021: 56 · 2020: 64 · 2019: 25
FWCI
44.01
Type
journal article
Language
en
Open access
Locations
  • Nature Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR003167, UL1TR000371)
  • National Human Genome Research Institute (U01HG009379, T32HG002295)
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (UH2AR067679, UH2AR067677, UH2AR067685, UH2AR067681, UH2AR067689, F31AR070582, UH2AR067676, UH2AR067694, UH2AR067691, UH2AR067690, UH2AR067688, UM2AR067678)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
Keywords
lupus nephritis, type I interferon response, renal tubular epithelial cells, keratinocytes, renal fibrosis, treatment non-response, skin biopsy, disease heterogeneity, membranous lupus nephritis, proliferative lupus nephritis, single-cell transcriptomics, personalized treatment
MeSH terms
Biopsy, Fibrosis, Humans, Interferon Type I, Kidney Tubules, Lupus Nephritis, Protein Binding, Skin, Signal Transduction, Keratinocytes, Extracellular Matrix Proteins, Cell Lineage, Computational Biology, Gene Expression Profiling, Single-Cell Analysis, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review